Proactive Investors - Run By Investors For Investors

Seraxis has 'mapped the path' to clinical testing with its SeraGraft technology

Seraxis Inc CEO Williams Rust sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The privately held biotechnology company, based in Singapore and the United States, uses proprietary technologies to develop a cell therapy that functions shortly after transplantation in diabetic animals and a device, SeraGraft that safely protects human pancreas cells from the immune system of animal hosts without the need for pharmacologic immunosuppression

View full SERXA profile View Profile

Seraxis Inc Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use